LifeStance Health GroupLFST +3.58%56 Debt-to-EBITDA is 3.29 as of Mar. 2026, which is 91% above its 10-year median of 1.72. GuruFocus rates LFST with a GF Score™ of 56/100 and a GF Value™ of $8.23 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 476 Healthcare Providers & Services companies, LifeStance Health Group ranks worse than 73.32% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for LifeStance Health Group's Debt-to-EBITDA or its related term are showing as below:
LFST'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.87 Med: 1.72 Max: 12.17
Current: 4.67
During the past 7 years, the highest Debt-to-EBITDA Ratio of LifeStance Health Group was 12.17. The lowest was -4.87. And the median was 1.72.
LFST's Debt-to-EBITDA is ranked worse than 73.32% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs LFST: 4.67
LifeStance Health Group (NAS:LFST) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
LifeStance Health Group Debt-to-EBITDA Related Terms
LifeStance Health Group Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, LifeStance Health Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeStance Health Group Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LifeStance Health Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LifeStance Health Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
LifeStance Health Group (LFST) has a Debt-to-EBITDA of 3.29 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on LifeStance Health Group. This is 91% above median its historical median of 1.72. According to the industry distribution chart, LifeStance Health Group ranks #349 out of 476 companies in the Healthcare Providers & Services industry, placing it in the top 73.3%.
Is LifeStance Health Group's Debt-to-EBITDA too high?
LifeStance Health Group's current Debt-to-EBITDA of 3.29 is 91% above median its 10-year median of 1.72. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. LifeStance Health Group's value of 3.29 is 46.2% above this industry median. Based on the distribution chart, LifeStance Health Group ranks #349 out of 476 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, LifeStance Health Group has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LifeStance Health Group's Debt-to-EBITDA compare to CON and BKD?
According to the Healthcare Providers & Services industry distribution chart, LifeStance Health Group ranks #349 out of 476 companies for Debt-to-EBITDA. This places LifeStance Health Group in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. LifeStance Health Group's value of 3.29 is 46.2% above this benchmark. While the company's 10-year median is 1.72 vs. the industry median of 2.25, LifeStance Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeStance Health Group's current Debt-to-EBITDA of 3.29 is 46.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on LifeStance Health Group. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeStance Health Group's current Debt-to-EBITDA is 3.29, which is 91% above median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeStance Health Group stock overvalued right now?
Based on GuruFocus' analysis, LifeStance Health Group (LFST) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.23, compared to a current price of $10.71 — trading 30.1% above its estimated fair value. The current Debt-to-EBITDA is 3.29, which is 91% above median its 10-year median of 1.72 and 46.2% above the Healthcare Providers & Services industry median of 2.25. LifeStance Health Group's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For LifeStance Health Group (LFST), the current Debt-to-EBITDA is 3.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeStance Health Group (LFST) Overvalued in 2026?
Based on GuruFocus' analysis, LifeStance Health Group stock appears to be overvalued.
The current stock price of $10.71 is trading 30.1% above its estimated GF Value™ of $8.23.
GuruFocus considers LifeStance Health Group to be Significantly Overvalued.
Key valuation signals for LFST:
Debt-to-EBITDA: 3.29 (91% above median its 10-year median of 1.72)
GF Value™: $8.23 vs. price of $10.71 (30.1% above fair value)
Industry Position: 46.2% above the Healthcare Providers & Services median (#349 of 476)
No single metric tells the full story. See the LFST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
56GF Score
Get the complete analysis for LFST
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFST has been successfully added to your 
